Astellas Singapore has announced that the Health Sciences Authority (HSA) of Singapore has approved VEOZA™ (fezolinetant) 45 mg for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. The approval is supported by data from the BRIGHT SKY™ clinical program, which encompassed three Phase 3 studies involving over 3,000 women across Europe, the United States, and Canada.

VMS—which include hot flushes and night sweats—are among the most common symptoms of menopause, affecting over 50% of women globally and approximately 19% of women in Singapore.¹² These symptoms result from hormonal fluctuations, particularly the decline in estrogen, disrupting the balance with neurokinin B (NKB), a key brain chemical regulating the body’s temperature control center.⁷

A 2023 study found that over 60% of Singaporean women experienced at least one moderate to extremely severe menopausal symptom, with VMS being the most prevalent.²

“This approval marks yet another significant milestone for our company, fezolinetant, and women’s health,” said Aycin Oguz, General Manager, Malaysia & Singapore, Astellas. “At Astellas, we are committed to delivering innovative therapies for areas of unmet need. With VEOZA™, we are proud to offer a novel, non-hormonal treatment option to women experiencing moderate to severe VMS.”

“VEOZA™ represents a meaningful advancement in how we address vasomotor symptoms,” added Rebecca Chng, Head, Medical Affairs, Astellas Pharma Singapore and Malaysia. “Its unique, non-hormonal mechanism of action targets the root cause of VMS and has been shown to significantly reduce both frequency and severity of hot flushes. We are proud to expand access to this evidence-based solution for women in Singapore.”

Fezolinetant was first approved by the U.S. Food and Drug Administration (FDA) in May 2023.⁸ In Singapore, VEOZA™ was officially authorised for use on 5 March 2025. Women experiencing symptoms of menopause are encouraged to speak with their healthcare providers about whether VEOZA™ is right for them.